RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert Kirken to Dose-Response Relationship, Drug

This is a "connection" page, showing publications Robert Kirken has written about Dose-Response Relationship, Drug.
  1. Nagy ZS, Ross JA, Rodriguez G, Bader J, Dimmock J, Kirken RA. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways. FEBS Lett. 2010 Apr 16; 584(8):1515-20.
    View in: PubMed
    Score: 0.072
  2. Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol Cancer. 2009 Aug 26; 8:67.
    View in: PubMed
    Score: 0.069
  3. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kahan BD, Kirken RA. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15; 99(2):680-9.
    View in: PubMed
    Score: 0.041
  4. Wang M, Kirken R, Behbod F, Erwin-Cohen R, Stepkowski SM, Kahan BD. Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection. Transplant Proc. 2001 Feb-Mar; 33(1-2):201.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support